The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Chimerix
Stock and Other Ownership Interests - Chimerix
Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma.
 
Yazmin Odia
Consulting or Advisory Role - GammaTile; Istari Oncology; PharPoint Research
Research Funding - Bristol-Myers Squibb (Inst); Novocure (Inst)
 
Carl Johannes Koschmann
No Relationships to Disclose
 
Rohinton Tarapore
No Relationships to Disclose
 
Jeffrey Allen
No Relationships to Disclose
 
Wafik Tharwat Zaky
No Relationships to Disclose
 
Matthew David Hall
Other Relationship - Proton Therapy Collaborative Group
 
Doured Daghistani
No Relationships to Disclose
 
Ziad Khatib
No Relationships to Disclose
 
Dolly Aguilera
No Relationships to Disclose
 
Tobey J. MacDonald
No Relationships to Disclose
 
Peter de Blank
No Relationships to Disclose
 
Susan L. McGovern
Consulting or Advisory Role - Chimerix
 
Sabine Mueller
Research Funding - Midatech Pharma; Regeneron
 
Cassie Kline
Research Funding - Curis; Ipsen; Midatech Pharma; Regeneron
 
Nicholas A. Vitanza
No Relationships to Disclose
 
Joshua E. Allen
Employment - Chimerix; Oncoceutics
Leadership - Chimerix; Oncoceutics
Stock and Other Ownership Interests - Chimerix; Chimerix; Oncoceutics; Oncoceutics
Patents, Royalties, Other Intellectual Property - ONC201-related patents; ONC201-related patents
Travel, Accommodations, Expenses - Oncoceutics; Oncoceutics; Oncoceutics; Oncoceutics; Oncoceutics
 
Sharon L. Gardner
No Relationships to Disclose